

Occurrence and characteristics of cytotoxic necrotizing factors, cytolethal distending toxins and other virulence factors in *Escherichia coli* from human blood and faecal samples

H. J. KADHUM¹, D. FINLAY², M. T. ROWE^{1,3*}, I. G. WILSON⁴ AND H. J. BALL²

¹ Department of Food Science (Food Microbiology), The Queen's University of Belfast, Newforge Lane, Belfast, UK

² Agri-Food and Biosciences Institute (AFBI) Veterinary Science Division, Belfast, UK

³ Agriculture, Food and Environmental Science Division (Food Microbiology Branch), Belfast, UK

⁴ Northern Ireland Public Health Laboratory, Belfast City Hospital, Belfast, UK

(Accepted 23 June 2007; first published online 3 August 2007)

SUMMARY

Escherichia coli isolates from human blood ($n=266$) and faecal ($n=237$) samples were examined for cytotoxic necrotizing factors 1 and 2 (CNF 1 and 2), cytolethal distending toxin (CDT), and putative virulence factors that have been associated with disease conditions in humans and animals. PCR showed that the chromosomally encoded, Rho-activating, *CNF1* (68/544, 12.5%) was more common than the transmissible plasmid-borne *CNF2* (3/544, 0.6%). The relative risk of having either CNF or CDT toxin genes in blood compared to faecal isolates was 3.88 (95% CI 2.36–6.38). This was highly significant ($P<0.0001$) and demonstrates the importance of these factors in bloodstream infections. Fifty-one of 65 (78%) *E. coli* bearing *CNF1* and 11 of 21 (52%) of *E. coli* bearing *CDT* also carried the pyelonephritis-associated pilus gene, *papG*. The S fimbrial adhesin gene, *sfa*, was found in 57 blood (21%) and eight faecal samples (3%). The F17 fimbrial adhesin gene and afimbrial adhesin gene *afa* did not occur frequently. Haemolysin (*hly*) was found in all of the isolates tested. Further studies must be designed to identify the clinical significance of these genes and their role in pathogenesis.

INTRODUCTION

Pathogenicity in *Escherichia coli* strains is determined by the presence of specific virulence factors, such as toxins and adhesins, that help overcome host defences and facilitate colonization, resulting in the development of intestinal and extra-intestinal disease [1–4]. The significance of toxins and pathogenicity determinants in those *E. coli* strains responsible for infections at various body sites is being elucidated through molecular and tissue culture studies [5]. Such work

should enable commensal and pathogenic strains to be distinguished and therefore assist diagnosis and treatment.

The characterized toxins include the cytotoxic necrotizing factors (CNFs) and cytolethal distending toxins (CDTs), both of which were first isolated from enteric pathogens from humans [3, 6]. Two major classes of CNF toxins have been identified [7]. Both cause profound reorganization of the cytoskeleton characterized mainly by the irreversible formation of thick bundles of actin stress fibres which inhibits cell division [8]. CNF1 causes the enlargement, multinucleation and rounding of HeLa cells, and has been demonstrated in haemolysin-producing *E. coli* strains isolated from humans with septicaemia and enteritis

* Author for correspondence: Dr M. T. Rowe, Agriculture, Food and Environmental Science Division (Food Microbiology Branch), Newforge Lane, Belfast BT9 5PX, UK.
(Email: Michael.Rowe@afbini.gov.uk)

in Italy [6, 9] and from pigs with diarrhoea [10]. CNF2 causes enlargement, multinucleation and elongation of HeLa cells, and has been demonstrated largely in *E. coli* strains isolated from calves and lambs with diarrhoea [11] and septicaemia [12]. CNF1 strains have mostly been isolated from extraintestinal infections from humans with urinary tract infections (UTIs) and occasionally children with diarrhoea. The majority of CNF2 strains have been isolated from calves with septicaemia or diarrhoea [13].

CDT-producing *E. coli* strains were first described by Johnson & Lior [3] who isolated them from children with enteritis. Currently four CDTs have been differentiated by gene sequence. The CDTs, or close homologues, are also produced by other bacteria such as *Campylobacter* spp. [14], *Shigella dysenteriae* [15] and *Haemophilus ducreyi* [16]. When tested in HeLa cells, CDTs produce giant mononucleated cells caused by an irreversible block in the cell cycle at the G2/M stage [17]. Cellular death follows this elongation. As with CNFs, there is debate as to whether CDT-harboring *E. coli* are pathogenic to humans. For example, in a case-control study of CDT-producing *E. coli* in Bangladeshi children Albert *et al.* [4] found that, although CDT-positive *E. coli* were isolated from more children with diarrhoea than healthy controls, the difference was not statistically significant.

Additional toxins, haemolysins (*hly*), commonly present in pathogenic *E. coli* strains, are also thought to contribute to the virulence of these strains [9, 18]. A number of adhesins have been described in pathogenic *E. coli* strains associated with intestinal and extraintestinal diseases. Adhesins are either associated with fimbrial cell surface structures such as P-fimbriae, S-fimbriae and F17, or not associated with fimbriae and designated as afimbrial adhesins (*afa*). These factors are encoded by the *pap*, *sfa*, *F17* and *afa* related gene clusters respectively [19–22]. Furthermore, the CNF toxins have been thought to be elaborated only by *E. coli* strains. However, it has been reported that cell extracts from *Yersinia pseudotuberculosis* induced multinucleation in Hep-2 cells in a manner similar to the effect of CNF caused by *E. coli* strains. The nucleotide sequence of the *Yersinia CNF* gene was found to be 65% similar to the *CNF* gene of *E. coli* strains [23].

This study investigated the incidence of *CNF*- and *CDT*-harboring *E. coli* strains isolated from patients and controls in Northern Ireland using PCR assays for the specific detection of *CNF* and *CDT* toxins and other pathogenicity factors. The results will enable the

design of studies of suitable power to assess the importance of *CNF* and *CDT* production to clinical condition and outcome, since their relevance currently remains unclear.

MATERIALS AND METHODS

Bacterial strains

E. coli isolates from a total of 544 humans were used in this study. Isolates were cultured from the blood ($n = 266$) and faecal ($n = 237$) samples of adult patients in Belfast City Hospital, a 900-bed teaching hospital. Faecal samples were examined diagnostically for a variety of pathogens by standard methods, but only *E. coli* isolates from them are reported in this study. For the purposes of this study blood isolates were treated as individual samples and not collated into a series for individual patients to exclude incidental contamination, although this is the hospital practice for case diagnosis of septicaemia. Blood cultures were not done for patients with diarrhoea unless septicaemia was also suspected, and it would have been unethical to perform venepuncture in the absence of this suspicion. No controls for blood isolates were available since the blood of healthy individuals is sterile. More than 80% of the faecal samples originated from adult hospital patients, the remainder being submitted by local general practitioners and included children's specimens. To maintain confidentiality, patient records were not accessed. As a consequence of this, it is possible that a few samples were repeat cultures from the same patient. The number of repeat patient samples in this hospital is <1%. The case mix of the hospital is such that around 10–20% of the blood samples came from immunocompromised haematology, oncology and renal patients where it is recognized that it is common for septicaemia to originate from intestinal microflora. Paired specimens of blood and urine would not have been taken in all cases we examined, and confidentiality precludes this being investigated retrospectively. *E. coli* isolates were processed on arrival at the laboratory, or after overnight storage at 4 °C. Cultures from fresh patient specimens (peri-anal swabs for asymptomatic control subjects, age range 19–60 years, who worked in food and veterinary microbiology laboratories, $n = 41$) were subcultured overnight on blood agar plates at 37 °C. Control volunteers were not phlebotomized for ethical reasons. Single colonies were tested by multiplex PCR

as described previously [24] and HeLa cell cytotoxicity assays. Positive strains were confirmed as *E. coli* by biochemical tests with the API 20E system (bioMérieux, Basingstoke, UK).

Cytotoxicity assay

E. coli strains were grown on blood agar overnight at 37 °C. One loopful of colony growth was suspended in 0.5 ml sterile phosphate buffered saline (PBS; 0.1 M, pH 7.2). The suspension was frozen at –70 °C and thawed at room temperature, three times. After centrifugation at 10 000 g for 10 min, the supernatants were stored at –20 °C until used. The cytotoxicity assay was performed with HeLa cells as previously described [3].

Haemolysin PCR assay

E. coli strains were cultured overnight at 37 °C on 5% washed bovine blood agar, and haemolytic areas larger than the overlying colony were recorded as positive. Positive haemolysins were tested for α -haemolysin by using specific primers [25]. Amplifications were performed in a 25 μ l reaction mixture containing 2–2.5 mmol/l MgCl₂, 0.32 mmol/l of each dNTP, 1.2 μ mol/l of the primer pair and 0.5 U *Taq* DNA polymerase in PCR buffer (10 mmol/l Tris–HCl, 50 mmol/l KCl; pH 8.3). The thermal reaction parameters for the PCR were 94 °C for 5 min for 1 cycle, followed by 30 cycles of denaturing at 94 °C for 1 min, annealing at 48 °C for 1 min and extension at 72 °C for 1 min before a final extension step at 72 °C for 10 min.

PCR assays for other pathogenicity determinant genes

Primed sets are listed in Table 1. Amplifications were performed under the conditions used above except that annealing was at 63 °C for 1 min.

Serogrouping

The somatic (O) antigen of *E. coli* strains was determined by slide agglutination using a collection of 71 antisera that were available at the Veterinary Sciences Division where this work was carried out. Hospital isolates are not routinely serotyped. This collection was established largely for the identification of strains of veterinary significance and consisted of O1, O2, O3, O4, O5, O6, O7, O8, O9, O10, O11, O15, O17,

O18, O20, O21, O22, O26, O32, O35, O39, O43, O45, O54, O55, O64, O65, O71, O73, O75, O78, O81, O82, O86, O87, O88, O91, O92, O100, O101, O103, O105, O108, O109, O111, O113, O114, O115, O116, O117, O118, O119, O121, O123, O125, O126, O128, O130, O132, O137, O138, O139, O141, O145, O146, O147, O149, O153, O157, O162 and O168.

RESULTS

Table 2 shows a total of 74/266 (27.8%) blood strains were PCR positive for a toxin [95% confidence interval (CI) 22.5–33.6]. Fifty-two of these (20%) had *CNF* only, 18 (7%) had *CDT* only, and four (2%) had both toxin groups. From the 237 faecal strains, 17 (7%, 95% CI 4–11) were toxin PCR positive, of which nine (4%) had *CNF* only, four (2%) had *CDT* only and 4 (2%) had both toxin groups.

Table 3 summarizes the results obtained with the *CNF*-positive strains, using the multiplex PCR for the specific detection of *CNF1* and *CNF2* and *CDT1-4*. All 52 *CNF*-producing blood strains were *CNF1*, three were *CNF1/CDT1* and one was *CNF1/CDT4*. Eighteen of the blood strains were *CDT* only, 16 with *CDT1* and two with *CDT4*. Of the 13 *CNF* encoding faecal strains, nine were *CNF1*, two were *CNF1/CDT1* and two were *CNF2/CDT3*. Another four faecal strains were *CDT4* only. Two toxin-positive strains were isolated from the control faecal samples. One was *CNF1* and the other was *CNF2/CDT3*. All of the PCR toxin results were confirmed by the HeLa cell cytotoxicity assay, for both *CNF* and *CDT* toxins.

Genes for toxins and virulence factors were much more common in patient blood specimens than control faecal samples. Only two of the 41 healthy control faecal samples (4.9%, 95% CI 0.6–16.5) possessed these toxin genes. The relative risk of having either *CNF* or *CDT* toxin genes in patient compared to control faecal samples was 1.47 (95% CI 0.35–6.13; Fisher's exact test). Although there is no statistical evidence of an increased risk ($P=0.45$), the 95% confidence interval is very wide and includes the possibility of a true sixfold increased risk. The relative risk of having either *CNF* or *CDT* toxin genes in blood compared to faecal isolates was 3.88 (95% CI 2.36–6.38). This was highly significant ($P<0.0001$) and reflects the greater importance of *E. coli* isolates as a cause of bloodstream infections than in faeces where they may be less likely to be a cause of symptoms. The limited number of control samples

Table 1. *Primer sequences used for PCR assays*

Gene	Virulence factor	Primer sequences	Ref./Source
<i>CNF1</i>	Cytotoxic necrotizing factor	5'-GGGGGAAGTACAGAAGAATTA-3' 5'-TTGCCGTCCACTCTCTCACCAGT-3' 5'-TATATAGTCGTC AAGATGGA-3' 5'-CACTAAGCTTTACAATATTGAC-3'	[43]
<i>CNF2</i>	Cytotoxic necrotizing factor	5'-TATCATA CGGCAGGAGGAAGCACC-3' 5'-GTCACAATAGACAATAATTTTCCG-3'	[43]
<i>CDT1</i>	Cytolethal distending toxin	5'-CAATAGTCGCCACAGGA-3' 5'-ATAATCAAGAACCACCAC-3'	*
<i>CDT2</i>	Cytolethal distending toxin	5'-GAAAATAAATGGAATATAAATGTCCG-3' 5'-TTTGTGTTGCCGCCGCTGGTGAAA-3'	*
<i>CDT3</i>	Cytolethal distending toxin	5'-GAAAATAAATGGAATATAAATGTCCG-3' 5'-TTTGTGTCGGTGCAGCAGGGAAAA-3'	*
<i>CDT4</i>	Cytolethal distending toxin	5'-CCTGATGGTTCAGGAGGCTGGTTC-3' 5'-TTGCTCCAGAATCTATACCT-3'	*
<i>papG I</i>	Pyelonephritis-associated pilus	5'-TCGTGCTCAGGTCCGGAATTT-3' 5'-TGGATCCCCCAACATTATCG-3'	[44]
<i>papG II</i>	Pyelonephritis-associated pilus	5'-GGGATGAGCGGGCCTTTGAT-3' 5'-CGGGCCCCAAGTAACTCG-3'	[44]
<i>papG III</i>	Pyelonephritis-associated pilus	5'-GGCCTGCAATGGATTTACCTGG-3' 5'-CCACCAATGACCATGCCAGAC-3'	[44]
<i>sfa</i>	S fimbrial adhesin	5'-CTCCGGAGA ACTGGGTGCATCTTAC-3' 5'-CGGAGGAGTAATTACAAACCTGGCA-3'	[21]
<i>afa</i>	Afimbrial adhesin	5'-GCTGGGCAGCAA ACTGATAACTCTC-3' 5'-CATCAAGCTGTTTGTTCGTCGCCCG-3'	[21]
<i>F17 family</i>	Fimbrial adhesin	5'-GCAGAAAATTCAATTTATCCTTGG-3' 5'-CTGATAAGCGATGGTGTAATTAAC-3'	[19]
<i>F17b</i>	Fimbrial adhesin	5'-GCAGAAAATTCAATTTATCCTTGG-3' 5'-CAACTAACGGGATGTACAGTTTC-3'	[19]
<i>hly</i>	α -haemolysin	5'-AACAAAGGATAAGCACTGTTCTGGCT-3' 5'-ACCATATAAGCGGTCATTCCCGTCA-3'	[25]

* Gift from Eric Oswald.

Table 2. *Cytotoxic necrotizing factor (CNF) and cytolethal distending toxin (CDT) producing E. coli strains from human blood and faecal samples*

Source of specimen	No. samples tested	Total no. toxin + ve (%)	CNF only (%)	CDT only (%)	CNF and CDT (%)
Blood	266	74 (28)	52 (20)	18 (7)	4 (2)
Faecal samples					
Patients	237	17 (7)	9 (4)	4 (2)	4 (2)
Controls	41	2 (5)	1 (3)	—	1 (3)
Total	544	93 (17)	62 (11)	22 (4)	9 (2)

gave little power to detect differences between patients and controls, and a larger study would be informative.

The presence of genes encoding F17 fimbriae, *papG*, *sfa*, *afa* and the expression of α -*hly* in the CNF1-, CNF2-, and CDT-producing strains is also

summarized in Table 3. Most factor patterns contained five or fewer strains. Three characteristic factor patterns containing more than five strains were prominent. A group of 35 were from the CNF1 patient blood strains, seven from patient faecal samples, and one from control faecal samples (*CNF1*, *papG*, *sfa*,

Table 3. Distribution of *papG*, *sfa*, *afa*, *F17* and *hly* in *CNF1*, *CNF2*, *CDT1-4* positive *E. coli* strains

Toxin	Source of specimen	No. toxin +ve	No. factor +ve	Subtypes of <i>papG</i> (% of total)				
				<i>papG</i>	<i>sfa</i>	<i>afa</i>	<i>F17</i>	<i>hly</i>
<i>CNF1</i>	Blood	52	35	+	+	-	-	+
			5	+	-	-	-	+
			7	-	+	-	-	+
			2	+	-	+	-	+
			3	-	-	-	-	+
<i>CNF1/CDT1</i>	Blood	3	2	+	+	-	-	+
<i>CDT1</i>	Blood	16	8	+	+	-	-	+
			1	+	-	-	-	+
			3	-	+	-	-	+
			1	-	+	+	-	+
			2	-	-	+	-	+
			1	-	-	-	-	+
			1	-	-	+	-	+
<i>CNF1/CDT4</i>	Blood	1	1	+	-	-	-	+
<i>CDT4</i>	Blood	2	1	+	-	-	-	+
			1	-	-	+	-	+
<i>CNF1</i>	Patient faecal samples	9	7	+	+	-	-	+
			1	+	-	-	-	+
			1	+	-	+	-	+
<i>CNF1/CTD1</i>	Patient faecal samples	2	1	-	-	+	-	+
			1	-	-	-	-	+
<i>CDT4</i>	Patient faecal samples	4	1	+	-	-	-	+
			1	-	+	-	-	+
			1	-	-	-	+	+
			1	-	-	-	-	+
<i>CNF2/CDT3</i>	Patient faecal samples	2	2	-	-	-	-	+
<i>CNF1</i>	Control faecal samples	1	1	+	+	-	-	+
<i>CNF2/CDT3</i>	Control faecal samples	1	1	-	-	-	+	+

Table 4. The subtypes of *papG* expressed by *CNF1*- and *CDT*-positive *E. coli* strains

Toxin	Source of specimen	No. of toxin +ve	No. of <i>papG</i> +ve (%)	Subtypes of <i>papG</i> (% of total)				
				I	II	III	II-III	I-III
<i>CNF1</i>	Blood	52	43 (83)	1 (2)	13 (23)	22 (42)	6 (12)	1 (2)
<i>CDT</i>	Blood	18	9 (50)	—	5 (28)	4 (22)	—	—
<i>CNF1/CDT1</i>	Blood	3	2 (67)	—	—	2 (67)	—	—
<i>CNF1</i>	Patient faecal samples	9	5 (56)	—	2 (22)	3 (33)	—	—
<i>CNF1</i>	Control faecal samples	1	1 (100)	—	1 (100)	—	—	—

hly). A group of eight were from the *CDT* blood strains (*CDT1*, *papG*, *sfa*, *hly*), and a group of seven were from the *CNF1* blood strains (*CNF1*, *sfa*, *hly*).

Table 4 summarizes the subtypes of the *papG* gene detected in the toxigenic strains. Their distribution in the toxigenic strains, in descending order, was *III*, *II*

and both *II* and *III*. In addition one strain possessed *I*, and one strain had *I* and *III*. These subtypes were randomly distributed within the *papG*-positive strain divisions listed in Table 3.

Serotypes O2 (9), O4 (3), O6 (17), O18 (1), O22 (2), O26 (2), O27 (3) and 19 untypable were detected in the *CNF1* blood strains. Eleven (31%) of the O6 strains were from the large 35 encoding pattern group of strains described above. Serotypes O2 (7), O18 (3), O6 (1) and seven untypable were detected in the *CDT* blood strains. Four of the O2 strains and two of the O18 serogroups were from the similar encoding pattern group of 16 strains described above. The *CNF2* strains were O75 and O147.

Data concerning the age of the septicaemic cases were available. Analysis showed that the majority of the cases were in adults aged >50 years. From 52 *CNF1* and *CNF1/CDT1* and/or *CNF1/CDT4* cases and 18 *CDT* cases, 49 were in this age group, respectively. Similarly, from 192 cases from which toxigenic strains were not isolated, 140 involved adults aged >50 years. Insufficient information was available to make a meaningful analysis of diarrhoea cases by age.

DISCUSSION

Common and specific PCR primers were employed to amplify genes encoding the CNF and CDT toxins, α -hly and adhesins associated with these toxins. The PCR methods were specific for the detection of *E. coli* strains encoding these virulence factors. Although the factors examined have been previously implicated as virulence determinants, to the best of our knowledge, this is the first investigation of the presence of all of them in large numbers of strains isolated from clinical specimens. Several patterns of factors were detected in the strains examined, but the presence of common characteristic patterns in 35 (67%) of the *CNF1* blood strains and eight (50%) of the *CDT* blood strains are indicative of strain types with greater invasive potential. Additional toxigenic strains were apparent in the faecal samples, and the significance of the dominant factor pattern observed with seven (64%) of the *CNF1* strains was also persuasive. *CNF1* and *CNF2* are 85.7% genetically identical [26]. The *CNF1* and *CNF2* specific primers used in this study amplified unique sequences of different molecular size, enabling them to be used in a multiplex PCR. This assay enabled the differential detection of each toxin in the strains tested. Strains

expressing both toxins have never been recorded. In the present study, two *CNF2* strains belonging to serogroup O75 and O147 were recorded. *CNF2* has largely been detected in strains isolated from polygastric animals, and the predominance of *CNF1* strains from human sources in the present study supports the results of other studies [6, 27, 28].

The association of the *CNF1*-producing strains in this study with the other factors confirms the work of others [6, 28–32]. The combination of *CNF1*, α -hly and P-fimbriae genes has been demonstrated in the human uropathogenic strain, J96, possibly as a pathogenicity island [33]. These factors, together with *sfa*, were the predominant combination observed in 35 (67%) of the toxigenic blood strains. In addition, α -hly, P-fimbriae and *sfa* were also the factors encoded in the predominant *CDT*-expressing blood strains, suggesting a role in invasion for these toxin-associated factors. Seven CNF faecal strains also encoded the same pattern of associated factors. UTIs and septicaemia are frequently caused by gastrointestinal microorganisms and binding of P-fimbriae to the Gal α 1 \rightarrow 4Gal β disaccharide confers binding not only to urinary tract epithelial cells but also colonic epithelium. This is consistent with UTIs originating from faecal contamination.

The F17b fimbriae are well documented as an additional factor encoded by genes present in the *CNF2* Vir plasmid [34]. The absence of F17b fimbriae in the strains of this study was as expected. Although one blood *CDT* strain in this study was positive for the F17 family, the absence of *F17b* in *CNF1* strains was confirmed.

The significance of *CNF1* and α -hly has been evaluated in animal experiments employing genetically defined and mutant strains [35, 36]. The results suggested that these virulence factors induced pathological changes, including intestinal inflammation, giving rise to enterocolitis and bloody diarrhoea. Although outbreaks and cases of diarrhoea associated with *CNF1* strains have been reported [6, 37–39], the low incidence of *CNF1* faecal strains in the present study indicates its limited importance in the population investigated, and probably more widely.

A low incidence of CNF-encoding strains has been detected in faecal samples collected from healthy humans [27, 28]. Similar results were obtained in a preliminary study at this laboratory, where one *CNF1* and one *CNF2/CDT3* strains were isolated from 41 samples. Whether such isolates are potentially

pathogenic strains in asymptomatic carriers or are non-pathogenic strains cannot be determined with the information currently available. In general, factors that are associated with virulence are more commonly detected in strains isolated from patients than from healthy humans.

Various studies have reported the isolation of CDT-expressing strains from patients with a variety of diarrhoea symptoms and encephalopathy [4, 40]. Evidence from the use of a suckling mouse model suggests that the CDT toxin group causes secretory diarrhoea and necrosis of the colonic epithelium [15]. It is not clear whether these effects occur in human disease, and one study has suggested that CDT-producing *E. coli* strains are not associated with diarrhoea, as no statistical difference was found between their isolation from children with or without diarrhoea [4]. In the present study, there was a low prevalence of CDT strains isolated from faecal samples, 4/236 (2%), indicating their relative unimportance in Northern Ireland.

The association of CDT strains with *papG*, *sfa*, *F17b* and *α -hly* was highly variable in this study. The commonest pattern of factors displayed by eight of the 16 blood strains, was *papG*, *sfa* and *α -hly* positive. The pathogenic significance of this combination of factors remains to be clarified.

The serotypes found in the toxigenic strains in this investigation have been recorded in other studies which have reported that CNF1 strains belong to a limited number of serogroups, and that type O6 was the most common [6, 41]. In this investigation O6 strains were detected most commonly among *CNF1* strains, and O2 and O18 strains were found to be the most frequently identified in CDT strains.

The role of the CNF and CDT *E. coli* strains in septicaemia and/or diarrhoea in humans is not fully understood. A significant proportion of blood isolates may have originated from UTIs, particularly in elderly female patients where around half of bacteraemias are UTI related. The highest incidence of toxic blood strains was among elderly patients (aged >50 years). In this group, they are probably opportunistic pathogens. The finding of *E. coli* in blood is of clinical significance, but a small proportion of isolates may have been skin contaminants. Foodborne transmission may possibly occur [42], leading to a transient or colonizing alteration of the gastrointestinal flora. With accessory factors, these bacteria may give rise to UTIs, bacteraemia and septicaemia in a small proportion of cases. This work identifies the importance

of these *E. coli* strains in bloodstream infections and reports the frequencies of genes occurring in *E. coli* from patients' blood and faecal specimens. It provides baseline values that will assist the development of studies targeted more specifically to establish the clinical relevance of these pathogenicity determinants.

ACKNOWLEDGEMENTS

The provision of the *E. coli* clinical isolates by Barry McClurg, and critical comments by Dr Paul Rooney, Belfast City Hospital, Belfast, are gratefully acknowledged. The assistance of John Early, Food Microbiology Division, Newforge Lane, Belfast, and staff members of the Molecular Bacteriology and the Salmonella Laboratories at the Veterinary Sciences Division are also recognized. The authors are grateful for the supply of CDT1, 2, 3 and 4 primer sequences by Dr Eric Oswald (Laboratoire Associé INFRA-ENVT de Microbiologie Ecole Nationale Vétérinaire, Toulouse, France), and Nick Andrews (Health Protection Agency) for statistical advice.

DECLARATION OF INTEREST

None.

REFERENCES

1. Kaper JB, Nataro JP, Mobley HL. Pathogenic *Escherichia coli*. *Nature Reviews Microbiology* 2004; **2**: 123–140.
2. Krogfela KA. Bacterial adhesion: Genetics, biogenesis and role in pathogenesis of fimbrial adhesins of *Escherichia coli*. *Review of Infectious Diseases* 1991; **13**: 721–735.
3. Johnson WM, Loir H. A new heat-labile cytolethal distending toxin (CLDT) produced by *Escherichia coli* isolates from clinical material. *Microbial Pathogenesis* 1988; **4**: 103–113.
4. Albert MJ, *et al.* Controlled study of cytolethal distending toxin-producing *Escherichia coli* infections in Bangladeshi children. *Journal of Clinical Microbiology* 1996; **34**: 717–719.
5. Hoffmann C, Schmidt G. CNF and DNT. *Reviews of Physiology, Biochemistry and Pharmacology* 2004; **152**: 49–63.
6. Caprioli A, *et al.* Partial purification and characterization of an *Escherichia coli* toxic factor that induces morphological cell alterations. *Infection and Immunity* 1983; **39**: 1300–1306.
7. De Rycke J, *et al.* Evidence for two types of cytotoxic necrotizing factor in human and animal clinical isolates of *Escherichia coli*. *Journal of Clinical Microbiology* 1990; **28**: 694–699.

8. **Fiorentini C, et al.** Cytoskeleton changes induced in Hep-2 cells by the cytotoxic necrotising factor of *Escherichia coli*. *Toxicon* 1988; **26**: 1047–1056.
9. **Caprioli A, et al.** Cytotoxic necrotizing factor production by hemolytic strains of *Escherichia coli* causing extraintestinal infections. *Journal of Clinical Microbiology* 1987; **25**: 146–149.
10. **Penrith ML, Henton MM.** CNF1 toxin-producing strains of *Escherichia coli* isolated from weaner pigs with necrotic enteritis in South Africa. *Veterinary Science* 1995; **136**: 493–494.
11. **De Rycke J, Guillot JF, Boivin R.** Cytotoxins in non-enteropathogenic strains of *Escherichia coli* isolated from faeces of diarrhoeic calves. *Veterinary Microbiology* 1987; **15**: 137–150.
12. **Smith HW.** A search for transmissible pathogenic characters in invasive strains of *Escherichia coli*: The discovery of a plasmid-controlled lethal character closely associated, or identical, with colicin V. *Journal of General Microbiology* 1974; **83**: 95–111.
13. **Tavechio AT, et al.** Detection of cytotoxic necrotising factor types 1 and 2 among *Escherichia coli* isolates from Brazilian children with and without diarrhoea. *Memórias do Instituto Oswaldo Cruz* 2004; **99**: 811–813.
14. **Pickett CL, et al.** Prevalence of cytolethal distending toxin production in *Campylobacter jejuni* and relatedness of *Campylobacter* sp. *CdtB* genes. *Infection and Immunity* 1997; **64**: 2070–2078.
15. **Okuda J, et al.** Examination of diarrheagenicity of cytolethal distending toxin: suckling mouse response to the products of the *cdtABC* genes of *Shigella dysenteriae*. *Infection and Immunity* 1997; **65**: 428–433.
16. **Cope LD, et al.** A diffusible cytotoxin of *Haemophilus ducreyi*. *Proceedings of the National Academy of Sciences USA* 1997; **94**: 4056–4061.
17. **Comayras C, et al.** *Escherichia coli* cytolethal distending toxin blocks HeLa cell cycle at the G2/M transition by preventing *cdc2* protein kinase dephosphorylation and activation. *Infection and Immunity* 1997; **65**: 5088–5095.
18. **Blanco J, et al.** Characteristics of haemolytic *Escherichia coli* with particular reference to production of cytotoxic necrotizing factor type 1 (CNF1). *Research in Microbiology* 1992; **143**: 869–878.
19. **Bertin Y, et al.** Rapid and specific detection of F17-related pilin and adhesin genes in diarrhoeic and septicaemic *Escherichia coli* strains by multiplex PCR. *Journal of Clinical Microbiology* 1996; **34**: 2921–2928.
20. **Bertin Y, et al.** Association of genes encoding P fimbriae, CS31A antigen and EAST 1 toxin among CNF1 producing *Escherichia coli* strains from cattle with septicaemia and diarrhoea. *FEMS Microbiology Letters* 1998; **162**: 235–239.
21. **Le Bouguenec C, Archambaud M, Labigne A.** Rapid and specific detection of the *pap*, *afa* and *sfa* adhesin encoding operons in uropathogenic *Escherichia coli* strains by polymerase chain reaction. *Journal of Clinical Microbiology* 1992; **30**: 1189–1193.
22. **Mazouari KE, et al.** F17-like fimbriae from an invasive *Escherichia coli* strain producing cytotoxic necrotizing factor type 2 toxin. *Infection and Immunity* 1994; **62**: 2633–2638.
23. **Lockman HA, et al.** *Yersinia pseudotuberculosis* produces a cytotoxic necrotizing factor. *Infection and Immunity* 2002; **70**: 2708–2714.
24. **Kadhun HJ.** The incidence and persistence of necrotoxicogenic *Escherichia coli* in the food processing environment. 2003. Ph.D. Thesis. Belfast: The Queens University of Belfast.
25. **Fernandez-Prada C, et al.** Hemolysin-positive enteroaggregative and cell-detaching *Escherichia coli* strains cause oncosis of human monocyte-derived macrophages and apoptosis of murine J774 cells. *Infection and Immunity* 1998; **66**: 3918–3924.
26. **Oswald E, et al.** Specific DNA probes to detect *Escherichia coli* strains producing cytotoxic necrotizing factor type 1 or type 2. *Medical Microbiology* 1994; **40**: 428–434.
27. **Bisicchia R, et al.** Toxin production and haemagglutination in strains of *Escherichia coli* from diarrhea in Brescia, Italy. *Journal of Hygiene* 1985; **95**: 353–361.
28. **Blanco J, et al.** Virulence factors of bacteraemic *Escherichia coli* with particular reference to production of cytotoxic necrotizing factor (CNF) by P-fimbriated strains. *Journal of Medical Microbiology* 1990; **31**: 175–183.
29. **Arthur M, et al.** Molecular epidemiology of adhesin and hemolysin virulence factors among uropathogenic *Escherichia coli*. *Infection and Immunity* 1989; **57**: 303–313.
30. **Brauner A, et al.** Production of cytotoxic necrotizing factor, verocytotoxin and haemolysin by pyelonephritogenic *Escherichia coli*. *European Journal of Clinical Microbiological Infectious Disease* 1990; **9**: 762–767.
31. **Falbo V, Famiglietti M, Caprioli A.** Gene block production of cytotoxic necrotizing factor 1 and hemolysin in *Escherichia coli* isolates from extraintestinal infections. *Infection and Immunity* 1992; **60**: 2182–2187.
32. **Germani Y, et al.** Prevalence of enteropathogenic, enteroaggregative and diffusely adherent *Escherichia coli* among isolates from children with diarrhea in New Caledonia. *Journal of Infectious Diseases* 1996; **174**: 1124–1126.
33. **Blum G, et al.** Gene clusters encoding the cytotoxic necrotizing factor type 1, Prs-fimbriae and α -hemolysin from the pathogenicity island II of the uropathogenic *Escherichia coli* strain J96. *FEMS Microbiology Letters* 1995; **126**: 189–196.
34. **Oswald E, et al.** Virulence factors associated with cytotoxic necrotizing factor type two in bovine diarrhoeic and septicaemic strains of *Escherichia coli*. *Journal of Clinical Microbiology* 1991; **29**: 2522–2527.
35. **Elliott SJ, et al.** Characterization of the roles of haemolysin and other toxins in enteropathy caused by alpha-hemolytic *Escherichia coli* linked to human diarrhoea. *Infection and Immunity* 1998; **66**: 2040–2051.
36. **Wray C, et al.** Experimental infection of neonatal pigs with CNF toxin-producing strains of *Escherichia*

- coli*. *Research into Veterinary Science* 1993; **54**: 290–298.
37. **Blanco J, et al.** Enterotoxigenic and necrotizing *Escherichia coli* in human diarrhea in Spain. *European Journal of Epidemiology* 1992; **8**: 548–552.
 38. **Gunzburg ST, et al.** Diffuse and enteroaggregative patterns of adherence of enteric *Escherichia coli* isolated from aboriginal children from the Kimberley region of Western Australia. *Journal of Infectious Diseases* 1993; **167**: 755–758.
 39. **Necoletti M, et al.** Virulence factors of lactose-negative *Escherichia coli* strains isolated from children with diarrhea in Somalia. *Journal of Clinical Microbiology* 1988; **26**: 524–529.
 40. **Anderson JD, Johnson MW.** Gastroenteritis and encephalopathy associated with a strain of *Escherichia coli* O55:K59:H4 that produced a cytolethal distending toxin. *Pediatric Journal of Infectious Disease* 1987; **6**: 11–12.
 41. **Giugliano LG, et al.** Characterisation of necrotizing *Escherichia coli* strains isolated from diarrhoeic children in Brazil. *Review of Microbiology in Sao Paulo* 1995; **26**: 274–278.
 42. **Smith JL.** Foodborne illness in the elderly. *Journal of Food Protection* 1998; **61**: 1229–1239.
 43. **Burns A.** An investigation into the occurrence and detection of *Escherichia coli* producing cytotoxic necrotising factors. 1996. Ph.D. thesis. The Queen's University of Belfast.
 44. **Johnson WM, Brown JJ, Maslow JN.** Clonal distribution of the three alleles of the Gal (α 1-4) Gal-specific adhesin gene papG among *Escherichia coli* strains from patients with bacteremia. *Journal of Infectious Diseases* 1988; **177**: 651–661.